Novo Nordisk

Located in Bagsvaerd, Denmark, Novo Nordisk is a worldwide pharmaceutical corporation with manufacturing sites in nine different nations and branches or offices in an additional five.

The organization was created in 1989 as a result of the union of two Danish businesses that date back to the 1920s. The Apis bull, one of the holy animals of ancient Egypt, appears as the emblem for Novo Nordisk.

Novo Nordisk has around 48,000 employees worldwide and distributes its goods in 168 nations. The company is now regarded as Denmark's biggest pharmaceutical firm. Novo Holdings, a significant stakeholder who owns around 25% of the company's stock and 45% of the voting shares, controls Novo Nordisk.

Novo Nordisk is a manufacturer and distributor of pharmaceutical goods and services, specializing in diabetes treatment medications and equipment. Additionally, Novo Nordisk engages in the management of hemostasis, growth hormone therapy, and hormone replacement therapy. In addition to Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza, the company also produces a number of other medications under various brand names.

In collaboration with other business and governmental partners, Novo Nordisk is also engaged in government-funded research initiatives. InnoMed PredTox is one instance of a non-clinical safety evaluation tool. Within the framework of the Innovative Medicines Initiative launched by the European Commission and the European Federation of Pharmaceutical Industries and Associations, the company is expanding its activities in joint research projects.

Industry: Pharmaceuticals, Health care

Founded: 21 December 1923
Headquarters: Novo Allé, DK-2880, Bagsværd, Denmark
Website: https://www.novonordisk.com/